Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients
NCT04133259
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis B, Chronic
Interventions
DRUG:
Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody
DRUG:
Nucleoside/nucleotide analogues
Sponsor
Henlix, Inc